Table 3.

Rates per 1,000 Veteran smokers and trends of incident varenicline and comparison nicotine replacement therapy among Veterans smokers with mental health and no mental health diagnoses

	Mental Health Diagnosis						No Mental Health Diagnosis
	Varenicline			Nicotine Replacement Therapy			Varenicline			Nicotine Replacement Therapy
	Coef. (SE)	95% CI		Coef. (SE)	95% CI		Coef. (SE)	95% CI		Coef. (SE)	95% CI
Pre-Warning Period
Rate of use at peak (October 2007)	7.42 (0.27)	6.89 to 7.95		12.19 (0.58)	11.04 to 13.33		5.32 (0.18)	4.96 to 5.69		8.04 (0.40)	7.25 to 8.83
Slope during pre-warning period	−0.30 (0.15)	−0.59 to −0.01*		−0.49 (0.32)	−1.12 to 0.15		−0.24 (0.10)	−0.44 to −0.04*		−0.44 (0.22)	−0.87 to 0.00*
FDA Advisory Warning (February 2008)
Rate of use at start of period	3.96 (0.17)	3.62 to 4.29		10.51 (0.36)	9.79 to 11.23		2.91 (0.11)	2.69 to 3.14		6.34 (0.25)	5.84 to 6.83
Slope change from prior period	0.10 (0.15)	−0.19 to 0.39		0.75 (0.32)	0.11 to 1.38*		0.10 (0.10)	−0.10 to 0.30		0.59 (0.22)	0.15 to 1.03***
FDA Boxed Warning (July 2009)
Rate of use at start of black box warning	1.12 (0.09)	0.94 to 1.31		12.33 (0.24)	11.85 to 12.80		0.91 (0.07)	0.78 to 1.05		7.18 (0.15)	6.88 to 7.47
Slope change from prior period	0.19 (0.02)	0.15 to 0.23***		−0.29 (0.06)	−0.40 to −0.18***		0.13 (0.02)	0.10 to 0.16***		−0.17 (0.04)	−0.24 to −0.10***
Removal of the Boxed Warning (December 2016)
Rate of use at start of period	1.29 (0.14)	1 to 1.57		10.28 (0.37)	9.54 to 11.01		0.82 (0.1)	0.61 to 1.02		6.54 (0.23)	6.08 to 7
Slope change from prior period	0.02 (0.01)	0.01 to 0.03***		0.01 (0.02)	−0.03 to 0.05		0.01 (0.01)	0 to 0.02		−0.08 (0.01)	−0.1 to −0.06***
Rate of use at end of post-warning period	1.95 (0.14)	1.67 to 2.23		9.48 (0.37)	8.75 to 10.22		0.82 (0.1)	0.61 to 1.03		3.13 (0.23)	2.67 to 3.59

CL, confidence interval; Coef., coefficient; SE, standard error.

^*<0.05

^**<0.01

^***<0.001